Application of rituximab in the treatment of immune-related kidney diseases
10.16753/j.cnki.1008-2344.2025.03.011
- VernacularTitle:利妥昔单抗在免疫相关性肾脏疾病中的应用
- Author:
Rui GUO
1
;
Yinyin YE
1
Author Information
1. 皖南医学院弋矶山医院肾内科,安徽 芜湖 241001
- Publication Type:Journal Article
- Keywords:
rituximab;
minimal change nephrotic syndrome;
focal segmental glomerulosclerosis;
membranous nephropathy;
ANCA-associated vasculitis-induced renal injury;
lupus nephritis
- From:
Journal of Shenyang Medical College
2025;27(3):293-297
- CountryChina
- Language:Chinese
-
Abstract:
Rituximab is a monoclonal antibody targeting the CD20 antigen on the surface of B lymphocytes.Studies have shown that rituximab has brought hope for the treatment of malignant tumors and autoimmune diseases.In recent years,its application has expanded to immune-related renal diseases,including refractory minimal change nephrotic syndrome,focal segmental glomerulosclerosis,idiopathic membranous nephropathy,ANCA-associated vasculitis-induced renal injury,and lupus nephritis.This article reviews the application of rituximab in immune-related kidney diseases,providing a basis for the clinical treatment of related kidney diseases.
